You are here: Industry Insights > ICER

News List

Aurinia reports favourable assessment of LUPKYNIS in ICER pharmaceutical-technology
March 18, 2021
Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis.
ICER’s Evidence Report Finds Esketamine May Benefit Patients with Treatment-Resistant Depression but Exceeds Cost-Effectiveness Thresholds firstwordpharma
May 10, 2019
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of esketamine (Spravato™, Janssen) ...
ICER’s Evidence Report Finds Esketamine May Benefit Patients with Treatment-Resistant Depression but Exceeds Cost-Effectiveness Thresholds firstwordpharma
May 10, 2019
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of esketamine (Spravato™, Janssen) ...
ICER Posts Draft Scoping Document for the Assessment of Treatments for Rheumatoid Arthritis firstwordpharma
April 12, 2019
ICER Posts Draft Scoping Document for the Assessment of Treatments for Rheumatoid Arthritis.
ICER says price for Biogen's Spinraza, estimated value for Novartis' Zolgensma are too high firstwordpharma
April 04, 2019
The Institute for Clinical and Economic Review (ICER) on Wednesday issued a final report indicating that Biogen……
ICER says price for Biogen's Spinraza, estimated value for Novartis' Zolgensma are too high firstwordpharma
April 04, 2019
The Institute for Clinical and Economic Review (ICER) on Wednesday issued a final report indicating that Biogen and Ionis Pharmaceuticals' spinal muscle atrophy (SMA) therapy Spinraza (nusinersen) is not cost-effective at its current price.
ICER to Publish Upcoming Assessment on Additive Cardiovascular Disease Therapies firstwordpharma
February 23, 2019
ICER’s website provides timelines of key posting dates and public comment periods for the assessment of additive CVD therapies.
ICER finds Novartis' gene therapy Zolgensma cost effective up to $900 000 based on commonly used threshold; Biogen, Ionis' Spinraza would need firstwordpharma
February 23, 2019
Using an alternate measure of life years (LY) gained at the threshold between $100 000 and $150 000, ICER found that Zolgensma would be cost-effective between $710 000 and $1.5 million.
Cost watchdog ICER lays out plans to scrutinize pharma's costliest price hikes fiercepharma
January 22, 2019
The Institute for Clinical and Economic Review has been a thorn in pharma’s side for years, with its reviews often concluding drug launches are priced too high. Now, the pain for pharma could spread.
ICER Posts Draft Scoping Document for the Assessment of Treatments for Duchenne Muscular Dystrophy firstwordpharma
January 13, 2019
The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for Duchenne muscular dystrophy (DMD).

Previous page 1 2 Next page